GXV-813

GXV-813
Clinical data
Other names	GXV813; EX-A8078; EXA8078
Routes of; administration	Oral
Drug class	Muscarinic acetylcholine M4 receptor agonist
Identifiers
	IUPAC name (7S)-7-[4-[5-fluoro-2-(2-oxaspiro[3.3]heptan-6-yloxy)phenyl]piperidin-1-yl]-2-(1,3,4-oxadiazol-2-yl)-5-oxa-2-azaspiro[3.4]octane;
CAS Number	2640099-21-2;
PubChem CID	156248515;
UNII	ZPB5JA37X4;
Chemical and physical data
Formula	C25H31FN4O4
Molar mass	470.545 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC1C2=C(C=CC(=C2)F)OC3CC4(C3)COC4)[C@H]5CC6(CN(C6)C7=NN=CO7)OC5;
	InChI InChI=1S/C25H31FN4O4/c26-18-1-2-22(34-20-9-24(10-20)14-31-15-24)21(7-18)17-3-5-29(6-4-17)19-8-25(33-11-19)12-30(13-25)23-28-27-16-32-23/h1-2,7,16-17,19-20H,3-6,8-15H2/t19-/m0/s1; Key:ORGCUCREOUHRLJ-IBGZPJMESA-N;

GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M₄ receptor agonist which is under development for the treatment of schizophrenia.^[1]^[3]^[2]^[4] It is taken orally.^[1]^[2] The drug is under development by Novartis.^[1]^[3]^[2] As of March 2026, it is in phase 2 clinical trials for schizophrenia.^[1]^[3]^[2] The drug also is or was under development for another unspecified indication, but no recent development for this use has been reported.^[1] Two phase 2 trials for schizophrenia are underway and expected to be completed in April 2027.^[2]

References

1 2 3 4 5 6 "GXV 813". AdisInsight. 28 March 2026. Retrieved 7 June 2026.
1 2 3 4 5 6 "GXV-813 Drug Profile". Ozmosi. 1 January 1900. Retrieved 7 June 2026.
1 2 3 "Delving into the Latest Updates on GXV-813 with Synapse". Synapse. 20 March 2026. Retrieved 7 June 2026.
↑ US 20240140959, Calhoun A, Chen X, Gardinier KM, Hall EC, Jendza K, Labbe-Giguere N, Neef JA, Palacios DS, Qian M, Shultz MD, Thomson CG, Wang KY, Yang F, "2-azaspiro[3.4]octane derivatives as m4 agonists", published 30 October 2023, assigned to Novartis AG

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 3 4 5 6 "GXV 813". AdisInsight. 28 March 2026. Retrieved 7 June 2026.

[Ozmosi-2] 1 2 3 4 5 6 "GXV-813 Drug Profile". Ozmosi. 1 January 1900. Retrieved 7 June 2026.

[Synapse-3] 1 2 3 "Delving into the Latest Updates on GXV-813 with Synapse". Synapse. 20 March 2026. Retrieved 7 June 2026.

[US20240140959-4] US 20240140959, Calhoun A, Chen X, Gardinier KM, Hall EC, Jendza K, Labbe-Giguere N, Neef JA, Palacios DS, Qian M, Shultz MD, Thomson CG, Wang KY, Yang F, "2-azaspiro[3.4]octane derivatives as m4 agonists", published 30 October 2023, assigned to Novartis AG

[1]

[2]

[3]

[4]

See also

References